CYRX on Nasdaq
Cryoport, Inc.
In its 2026 annual report the company says: “We are a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with a strong focus on supporting the rapidly growing cell and gene therapy market. Our solutions are purpose-built to support a broad range of global life sciences markets, including biopharmaceutical and pharmaceutical companies, the animal health markets, reproductive medicine, academic institutions, research, and government agencies.”5 It is headquartered in Carson City, United States.2 Its shares trade on Nasdaq under the symbol CYRX.2
Price unavailable
Last updated Oct 21, 2026.
Overview
Compare with Phathom Pharmaceuticals, Inc., Syndax Pharmaceuticals Inc or Kamada Ltd., or pick any stock.
- TickerCYRX on Nasdaq2
- IndustryPharmaceutical Preparations2
- HeadquartersCarson City, United States2
- Incorporated inNV3
- Business address112 Westwood Place, Suite 350, Brentwood, Tn 370273
- Filer categoryAccelerated filer3
- Legal formProfit Corporation2
- LEI9845004D8538BT8JF6262
- StatusActive2
- LEI statusIssued and current2
- Registered address112 NORTH CURRY STREET, 89703 Carson City, United States2
- Registered withBusiness Center (Secretary of State), NV199010226192
See how the biggest companies compare on our leaderboards
We are a leading global provider of integrated, temperature-controlled supply chain solutions for the life sciences, with a strong focus on supporting the rapidly growing cell and gene therapy (“CGT”) market. Our solutions are purpose-built to support a broad range of global life sciences markets, including biopharmaceutical and pharmaceutical companies, the animal health markets, reproductive medicine, academic institutions, research, and government agencies. Our solutions help our customers ensure the safe, compliant storage, handling, and delivery of high value, temperature sensitive biological materials, including cell and gene therapies and immunotherapies.5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
47.1%Gross margin6
-20.9%Operating margin6
44.4%Net margin6
12.4%Revenue growth, 20256
15.6%Return on equity6
-$25.0MFree cash flow6
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 45% of the revenue Cryoport, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Product | $89.2M | $74.7M | $79.7M |
| BioLogistics Solutions | $65.9M | $67.0M | $78.1M |
| Bio Storage/Bio Services | $13.6M | $15.0M | $18.4M |
Business segments
Life Sciences Services brought in 57% of the revenue Cryoport, Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Life Sciences Services | $81.2M | $85.3M | $101.0M |
| Life Sciences Products | $87.5M | $71.4M | $75.1M |
Regions
Americas brought in 75% of the revenue Cryoport, Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| Americas | $117.9M | $113.5M | $131.3M |
| EMEA | $27.6M | $27.0M | $25.1M |
| Asia Pacific | $23.1M | $16.2M | $19.8M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue32¢$93.1M
- Research and development6¢$17.0M
- Selling, general and admin35¢$102.8M
- Income tax1¢$1.8M
- Profit27¢$78.3M
Out of $176.2M in revenue.6
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenue | $176.2M | $156.8M | $168.7M |
| Total cost of revenue | $93.1M | $87.1M | $93.3M |
| Gross margin | $83.1M | $69.7M | $75.3M |
| Selling, general and administrative | $102.8M | $109.8M | $108.3M |
| Engineering and development | $17.0M | $17.7M | $18.0M |
| Impairment loss | $63.8M | $49.6M | |
| Total operating costs and expenses | $119.9M | $191.3M | $175.9M |
| Loss from operations | -$36.8M | -$121.7M | -$100.5M |
| Investment income | $9.8M | $9.9M | $10.6M |
| Interest expense, net | -$2.4M | -$4.0M | -$5.6M |
| Gain on extinguishment of debt, net | $18.5M | $5.7M | |
| Other income (expense), net | -$2.8M | -$7.1M | $5.6M |
| Total other income, net | $4.6M | $17.3M | $16.3M |
| Loss from continuing operations before provision for income taxes | -$32.2M | -$104.3M | -$84.2M |
| Provision for income taxes | -$1.8M | -$359.0K | -$345.0K |
| Loss from continuing operations | -$34.0M | -$104.7M | -$84.6M |
| Income (loss) from discontinued operations, net | $112.3M | -$10.0M | -$15.0M |
| Net income (loss) | $78.3M | -$114.8M | -$99.6M |
| Paid-in-kind dividend on Series C convertible preferred stock | -$8.0M | -$8.0M | -$8.0M |
| Net income (loss) attributable to common stockholders | $70.3M | -$122.8M | -$107.6M |
| Net loss per share from continuing operations - basic (in dollars per share) | -$1 | -$2 | -$2 |
| Net income (loss) per share from discontinued operations - basic (in dollars per share) | $2 | -$0 | -$0 |
| Net income (loss) per share - basic (in dollars per share) | $1.40 | -$2.49 | -$2.21 |
| Weighted average common shares issued and outstanding - basic (in shares) | 50.1M shares | 49.3M shares | 48.7M shares |
| Net loss per share from continuing operations - diluted (in dollars per share) | -$1 | -$2 | -$2 |
| Net income (loss) per share from discontinued operations - diluted (in dollars per share) | $2 | -$0 | -$0 |
| Net income (loss) per share - diluted (in dollars per share) | $1.40 | -$2.49 | -$2.21 |
| Weighted average common shares issued and outstanding - diluted (in shares) | 50.1M shares | 49.3M shares | 48.7M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $250.5M | $34.1M | $35.2M | $29.2M |
| Short-term investments | $160.7M | $216.5M | ||
| Accounts receivable, net | $33.4M | $25.3M | ||
| Inventories | $23.2M | $21.5M | ||
| Prepaid expenses and other current assets | $8.4M | $7.9M | ||
| Current assets held for sale | $36.3M | |||
| Total current assets | $476.2M | $341.6M | ||
| Property and equipment, net | $85.4M | $80.0M | ||
| Operating lease right-of-use assets | $39.7M | $39.9M | ||
| Intangible assets, net | $138.1M | $147.9M | ||
| Goodwill | $22.4M | $20.6M | $76.4M | |
| Deposits | $2.1M | $2.0M | ||
| Deferred tax assets | $1.1M | $842.0K | ||
| Long-term assets held for sale | $70.7M | |||
| Total assets | $765.0M | $703.5M | ||
| Accounts payable and other accrued expenses | $15.3M | $15.9M | ||
| Accrued compensation and related expenses | $13.0M | $11.2M | ||
| Deferred revenue | $943.0K | $1.1M | ||
| Current portion of operating lease liabilities | $4.1M | $3.4M | ||
| Current portion of finance lease liabilities | $422.0K | $315.0K | ||
| Current portion of convertible senior notes, net of discount of $1.1 million and $0.1 million, respectively | $185.1M | $14.3M | ||
| Current portion of notes payable | $163.0K | $143.0K | ||
| Current portion of contingent consideration | $2.8M | |||
| Current liabilities held for sale | $15.4M | |||
| Total current liabilities | $219.0M | $64.6M | ||
| Convertible senior notes, net of current portion and discount of $0 and $2.3 million, respectively | $183.9M | |||
| Notes payable, net of current portion | $1.1M | $1.1M | ||
| Operating lease liabilities, net of current portion | $39.1M | $38.6M | ||
| Finance lease liabilities, net of current portion | $741.0K | $800.0K | ||
| Deferred tax liabilities | $1.4M | $804.0K | ||
| Other long-term liabilities | $444.0K | $295.0K | ||
| Contingent consideration, net of current portion | $629.0K | $3.8M | ||
| Long-term liabilities held for sale | $7.8M | |||
| Total liabilities | $262.4M | $301.6M | ||
| Common stock, $0.001 par value; 100,000,000 shares authorized; 49,850,793 and 49,908,254 issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $50.0K | $50.0K | ||
| Additional paid-in capital | $1.2B | $1.1B | ||
| Accumulated deficit | -$688.9M | -$757.2M | ||
| Accumulated other comprehensive loss | -$3.5M | -$20.9M | ||
| Total stockholders' equity | $502.6M | $401.9M | $489.0M | $555.8M |
| Total liabilities and stockholders' equity | $765.0M | $703.5M | ||
| Convertible senior notes current, discount | $1.1M | $100.0K | ||
| Convertible senior notes noncurrent, discount | $0 | $2.3M | ||
| Preferred stock, par value per share (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 2.5M shares | 2.5M shares | ||
| Common stock, par value per share (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized | 100.0M shares | 100.0M shares | ||
| Common stock, shares issued | 49.9M shares | 49.9M shares | ||
| Common stock, shares outstanding | 49.9M shares | 49.9M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $250.5M | $34.1M | $35.2M | $29.2M |
| Short-term investments | $160.7M | $216.5M | ||
| Accounts receivable, net | $33.4M | $25.3M | ||
| Inventories | $23.2M | $21.5M | ||
| Prepaid expenses and other current assets | $8.4M | $7.9M | ||
| Current assets held for sale | $36.3M | |||
| Total current assets | $476.2M | $341.6M | ||
| Property and equipment, net | $85.4M | $80.0M | ||
| Operating lease right-of-use assets | $39.7M | $39.9M | ||
| Intangible assets, net | $138.1M | $147.9M | ||
| Goodwill | $22.4M | $20.6M | $76.4M | |
| Deposits | $2.1M | $2.0M | ||
| Deferred tax assets | $1.1M | $842.0K | ||
| Long-term assets held for sale | $70.7M | |||
| Total assets | $765.0M | $703.5M | ||
| Accounts payable and other accrued expenses | $15.3M | $15.9M | ||
| Accrued compensation and related expenses | $13.0M | $11.2M | ||
| Deferred revenue | $943.0K | $1.1M | ||
| Current portion of operating lease liabilities | $4.1M | $3.4M | ||
| Current portion of finance lease liabilities | $422.0K | $315.0K | ||
| Current portion of convertible senior notes, net of discount of $1.1 million and $0.1 million, respectively | $185.1M | $14.3M | ||
| Current portion of notes payable | $163.0K | $143.0K | ||
| Current portion of contingent consideration | $2.8M | |||
| Current liabilities held for sale | $15.4M | |||
| Total current liabilities | $219.0M | $64.6M | ||
| Convertible senior notes, net of current portion and discount of $0 and $2.3 million, respectively | $183.9M | |||
| Notes payable, net of current portion | $1.1M | $1.1M | ||
| Operating lease liabilities, net of current portion | $39.1M | $38.6M | ||
| Finance lease liabilities, net of current portion | $741.0K | $800.0K | ||
| Deferred tax liabilities | $1.4M | $804.0K | ||
| Other long-term liabilities | $444.0K | $295.0K | ||
| Contingent consideration, net of current portion | $629.0K | $3.8M | ||
| Long-term liabilities held for sale | $7.8M | |||
| Total liabilities | $262.4M | $301.6M | ||
| Common stock, $0.001 par value; 100,000,000 shares authorized; 49,850,793 and 49,908,254 issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $50.0K | $50.0K | ||
| Additional paid-in capital | $1.2B | $1.1B | ||
| Accumulated deficit | -$688.9M | -$757.2M | ||
| Accumulated other comprehensive loss | -$3.5M | -$20.9M | ||
| Total stockholders' equity | $502.6M | $401.9M | $489.0M | $555.8M |
| Total liabilities and stockholders' equity | $765.0M | $703.5M | ||
| Convertible senior notes current, discount | $1.1M | $100.0K | ||
| Convertible senior notes noncurrent, discount | $0 | $2.3M | ||
| Preferred stock, par value per share (in dollars per share) | $0.00 | $0.00 | ||
| Preferred stock, shares authorized | 2.5M shares | 2.5M shares | ||
| Common stock, par value per share (in dollars per share) | $0.00 | $0.00 | ||
| Common stock, shares authorized | 100.0M shares | 100.0M shares | ||
| Common stock, shares issued | 49.9M shares | 49.9M shares | ||
| Common stock, shares outstanding | 49.9M shares | 49.9M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income (loss) | $78.3M | -$114.8M | -$99.6M |
| Impairment loss | $63.8M | $49.6M | |
| Depreciation and amortization | $27.7M | $30.8M | $27.5M |
| Amortization of debt discount | $1.2M | $1.9M | $2.5M |
| Non-cash operating lease expense | $6.6M | $5.8M | $5.1M |
| Unrealized (gain) loss on investments in equity securities | -$1.5M | $899.0K | -$1.3M |
| Realized loss on investments in equity securities | $48.0K | ||
| Realized loss on available-for-sale investments | $2.2M | $4.1M | $67.0K |
| Gain on extinguishment of debt | -$18.5M | -$5.7M | |
| Gain on divested business | -$117.0M | ||
| Stock-based compensation expense | $11.0M | $19.7M | $22.8M |
| Loss on disposal of property and equipment | $1.0M | $384.0K | $954.0K |
| Gain on insurance settlement | -$2.6M | ||
| Change in credit losses | $304.0K | -$242.0K | $822.0K |
| Excess and obsolete inventory | $393.0K | $234.0K | |
| Insurance proceeds for operations | $1.2M | ||
| Change in contingent consideration | -$5.2M | -$1.8M | -$890.0K |
| Accounts receivable | -$6.5M | -$4.1M | $3.7M |
| Inventories | -$2.2M | $3.3M | $1.5M |
| Prepaid expenses and other current assets | $1.4M | -$2.1M | -$103.0K |
| Deposits | -$189.0K | -$1.4M | -$663.0K |
| Operating lease liabilities | -$5.0M | -$5.3M | -$4.6M |
| Accounts payable and other accrued expenses | -$3.5M | -$76.0K | -$2.8M |
| Accrued compensation and related expenses | $1.9M | $1.9M | $2.9M |
| Deferred revenue | -$216.0K | -$179.0K | $842.0K |
| Net deferred tax liability | $661.0K | -$377.0K | -$2.0M |
| Net cash used in operating activities | -$8.6M | -$16.3M | -$757.0K |
| Purchases of property and equipment | -$16.4M | -$17.3M | -$38.8M |
| Insurance proceeds for loss of fixed assets | $976.0K | ||
| Software development costs | -$1.8M | -$2.9M | -$5.2M |
| Purchases of short-term investments | -$50.7M | -$42.7M | |
| Proceeds from divested business | $210.2M | ||
| Cash paid for acquisitions | -$313.0K | -$7.3M | |
| Sales/maturities of short-term investments | $59.6M | $249.1M | $130.0M |
| Patent and trademark costs | -$1.2M | -$1.1M | -$871.0K |
| Net cash provided by investing activities | $250.3M | $176.8M | $36.0M |
| Proceeds from exercise of stock options | $4.0M | $2.8M | $1.5M |
| Repurchase of common stock | -$10.0M | ||
| Repayment of notes payable | -$161.0K | -$141.0K | -$71.0K |
| Repayment of finance lease liabilities | -$530.0K | -$408.0K | -$202.0K |
| Net cash used in financing activities | -$21.1M | -$161.5M | -$23.8M |
| Effect of exchange rates on cash and cash equivalents | -$15.5M | -$18.0K | -$1.7M |
| Net change in cash and cash equivalents | $205.2M | -$1.1M | $9.8M |
| Cash paid for interest | $1.6M | $2.7M | $3.4M |
| Cash paid for income taxes | $2.2M | $1.4M | $1.5M |
| Operating lease right-of-use assets and operating lease liabilities | $6.6M | $21.0M | $11.1M |
| Net unrealized gain on available-for-sale debt securities | $1.5M | $2.9M | $6.7M |
| Reclassification of realized gain (loss) on available-for-sale debt securities to earnings | $3.0M | -$6.6M | -$3.0M |
| Paid-in-kind preferred stock dividend, including beneficial conversion feature | $8.0M | $8.0M | $8.0M |
| Fixed assets included in accounts payable and accrued liabilities | $218.0K | $103.0K | $442.0K |
| Intangible assets included in property and equipment | $252.0K | $8.7M | |
| Contingent consideration reclassed to accounts payable and accrued liabilities | $881.0K | ||
| Purchase of equipment through finance lease obligation | $388.0K | $936.0K | $1.1M |
No quarter-by-quarter statement was filed.
Corporate structure
Cryoport, Inc. sits at the top of its group. 15 entities, 9 countries on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Cryoport, Inc.
- CADIAN CAPITAL MANAGEMENT, LP Filed SCHEDULE 13G/A on Cryoport, Inc., latest Aug 14, 2026 (4 filings since Feb 14, 2024)
- Morgan Stanley Filed SCHEDULE 13G/A on Cryoport, Inc., latest Aug 13, 2026 (2 filings since Feb 8, 2024)
- INTEGRATED CORE STRATEGIES (US) LLC Filed SCHEDULE 13G/A on Cryoport, Inc., latest Jul 29, 2026 (6 filings since Sep 3, 2024)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on Cryoport, Inc., latest Mar 26, 2026 (6 filings since Feb 9, 2022)
- BROWN CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G/A on Cryoport, Inc., latest Feb 17, 2026 (10 filings since Mar 10, 2022)
- ALGER ASSOCIATES INC Filed SCHEDULE 13G/A on Cryoport, Inc., latest Aug 14, 2025 (7 filings since Jan 10, 2022)
- BlackRock Filed SC 13G/A on Cryoport, Inc., latest Jan 26, 2024 (3 filings since Feb 1, 2022)
- Invesco Filed SC 13G/A on Cryoport, Inc., latest Feb 8, 2023 (2 filings since Feb 9, 2022)
- Blackstone Holdings III L.P. Filed SC 13D/A on Cryoport, Inc., latest Nov 18, 2021
- Cryoport, Inc. Carson City, Nevada, United States
- Cryoport Netherlands B.V. Subsidiary · 100% · Hoofddorp, Netherlands
- Cryogene, Inc. Subsidiary · Texas, United States
- Cryoport Belgium SA Subsidiary · Belgium
- Cryoport France, SAS Subsidiary · France
- Cryoport Germany, GmbH Subsidiary · Germany
- Cryoport Japan GK Subsidiary · Japan
- Cryoport Systems, LLC Subsidiary · California, United States
- Cryoport UK Limited Subsidiary · United Kingdom
- MVE Biological Solutions (Chengdu) Co., Ltd. Subsidiary · China
- MVE Biological Solutions Australia Pty Limited Subsidiary · Australia
- MVE Biological Solutions Germany GmbH Subsidiary · Germany
- MVE Biological Solutions US, LLC Subsidiary · Delaware, United States
- SCI JA8 Subsidiary · France
- TEC4MED LifeScience GmbH Subsidiary · Germany
Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Cryoport, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $134.9M6 Dec 31, 2025 | $117.8M6 Dec 31, 2024 | +14.6% |
| Accumulated depreciation | $49.5M6 Dec 31, 2025 | $37.8M6 Dec 31, 2024 | +31.0% |
| Property and equipment, net | $85.4M6 Dec 31, 2025 | $80.0M6 Dec 31, 2024 | +6.8% |
| Operating-lease assets (leased space) | $39.7M6 Dec 31, 2025 | $39.9M6 Dec 31, 2024 | −0.5% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $250.5M6 Dec 31, 2025 | $34.1M6 Dec 31, 2024 | +633.8% |
| Marketable securities, current | $160.7M6 Dec 31, 2025 | $216.5M6 Dec 31, 2024 | −25.8% |
| Equity securities at fair value | $99.2M6 Dec 31, 2025 | $97.7M6 Dec 31, 2024 | +1.5% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $22.4M6 Dec 31, 2025 | $20.6M6 Dec 31, 2024 | +8.9% |
| Finite-lived intangibles, gross | $214.5M6 Dec 31, 2025 | $211.3M6 Dec 31, 2024 | +1.5% |
| Accumulated amortization | $67.2M6 Dec 31, 2025 | $54.1M6 Dec 31, 2024 | +24.2% |
| Finite-lived intangibles, net | $138.1M6 Dec 31, 2025 | $147.9M6 Dec 31, 2024 | −6.7% |
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $23.2M6 Dec 31, 2025 | $21.5M6 Dec 31, 2024 | +8.0% |
| Raw materials | $15.3M6 Dec 31, 2025 | $14.6M6 Dec 31, 2024 | +4.5% |
| Work in process | $1.2M6 Dec 31, 2025 | $1.1M6 Dec 31, 2024 | +7.3% |
| Finished goods | $6.7M6 Dec 31, 2025 | $5.7M6 Dec 31, 2024 | +16.9% |
Properties, in its own words
Our principal executive office is located in Brentwood, Tennessee. We lease or own various corporate, global logistics and supply chain centers, biostorage, manufacturing, and research and development facilities at 20 sites across the Americas, EMEA and APAC regions.
The following table summarizes our principal facilities and other materially important physical properties as of December 31, 2025:
The rest of Item 2
Location · Ownership · Use
Brentwood, Tennessee · Leased · Principal Executive Office
Irvine, California · Leased · Administrative, Global Supply Chain Center, and Research and Development Center
Morris Plains, New Jersey · Leased · Global Supply Chain Center and Administrative
Houston, Texas · Leased · Administrative, Global Supply Chain Center and Biostorage Center
Louvres (Paris Area), France · Leased · Global Supply Chain Center
Liège, Belgium · Leased · Bioservices, Cryopreservation, and Research and Development Center
Hoofddorp, the Netherlands · Leased · Global Logistics Center
Ball Ground, Georgia · Leased · Administrative, Manufacturing, and Research and Development Center
New Prague, Minnesota · Owned · Manufacturing
Chengdu, China · Owned · Administrative and Manufacturing
Clermont-Ferrand, France · Owned · Administrative and Bioservices
We believe that these facilities are adequate, suitable and of sufficient capacity to support our immediate needs.
Item 2 of the 10-K filed Mar 5, 2026.5
Leadership
Who has led Cryoport, Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
2010201520202025
- Chief executive officerJerrell Shelton May 8, 2013 to now14
- Chief executive officerLarry G. Stambaugh Aug 3, 2009 to Oct 5, 201015
- Chief executive officerPeter Berry Apr 24, 2008 to Dec 16, 200816
- ChairLarry G. Stambaugh Aug 3, 2009 to Feb 16, 201015
- PresidentJerrell Shelton Apr 3, 2019 to now17
- PresidentLarry G. Stambaugh Aug 3, 2009 to Oct 5, 201015
- Chief financial officerRobert Stefanovich Jul 7, 2011 to now18
- Chief financial officerCatherine M. Doll Aug 28, 2009 to Feb 16, 201019
Board members and other officers (21)
- Chief Digital and Tech OfficerEdward J. Zecchini Mar 19, 2024 to now20
- OfficerJerrell Shelton Sep 5, 2023 to Sep 5, 202321
- Chief Scientific OfficerMark W. Sawicki Mar 4, 2021 to now22
- Chief Commercial OfficerSteven L. Leatherman Apr 5, 2012 to Jul 2, 201323
- Chief Commercial OfficerMark Englehart Jun 10, 2011 to Jun 10, 201124
- OfficerMichael Bartholomew Sep 29, 2010 to Oct 18, 201025
- SecretaryCarlton M. Johnson Jul 9, 2009 to Oct 5, 201026
- Board memberLinda Baddour Mar 17, 2021 to now27
- Board memberRam M. Jagannath Oct 13, 2020 to Oct 13, 202028
- Board memberDaniel M. Hancock Jan 8, 2019 to now29
- Board memberRobert J. Hariri Nov 24, 2015 to now30
- Board memberRamkumar Mandalam Jun 20, 2014 to now31
- Board memberRichard G. Rathmann Apr 1, 2013 to Jan 4, 201632
- Board memberEdward J. Zecchini Oct 7, 2013 to May 16, 202333
- Board memberJerrell Shelton Oct 30, 2012 to now34
- Board memberKaren M. Muller Jun 13, 2011 to Dec 14, 201235
- Board memberJohn H. Bonde Feb 17, 2010 to Oct 5, 201036
- Board memberLarry G. Stambaugh Sep 17, 2010 to Oct 5, 201037
- Board memberCarlton M. Johnson Jul 9, 2009 to Oct 5, 201026
- Board memberAdam Michelin Aug 25, 2009 to Dec 14, 201238
- Board memberPeter Berry Apr 24, 2008 to May 11, 200916
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Cryogene, Inc. Texas4
- Cryoport Belgium SA Belgium4
- Cryoport France, SAS France4
- Cryoport Germany, GmbH Germany4
- Cryoport Japan GK Japan4
- Cryoport Netherlands BV The Netherlands4
- Cryoport Systems, LLC California4
- Cryoport UK Limited United Kingdom4
- MVE Biological Solutions (Chengdu) Co., Ltd. China4
- MVE Biological Solutions Australia Pty Limited Australia4
- MVE Biological Solutions Germany GmbH Germany4
- MVE Biological Solutions US, LLC Delaware4
- SCI JA8 France4
- TEC4MED LifeScience GmbH Germany4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Former names
- CRYOPORT SYSTEMS INCOct 20, 2005 to Oct 20, 20053
Timeline
- Aug 6, 20268-K Results of operations39
- Jun 9, 20268-K Shareholder vote40
- May 4, 20268-K Results of operations41
- Mar 3, 20268-K Results of operations42
- Nov 4, 20258-K Results of operations43
- Aug 6, 20258-K Results of operations44
- Jun 13, 20258-K Completed an acquisition or sale; Regulation FD disclosure45
- Jun 10, 20258-K Shareholder vote46
- May 7, 20258-K Results of operations47
- Mar 31, 20258-K Entered a material agreement; Regulation FD disclosure48
- Mar 4, 20258-K Results of operations49
- Nov 7, 20248-K Results of operations50
- May 8, 2013New chief executive Jerrell Shelton becomes CEO14
- Aug 3, 2009New chief executive Larry G. Stambaugh becomes CEO15
- Apr 24, 2008New chief executive Peter Berry becomes CEO16
- May 25, 1990Founded Cryoport, Inc. is founded2
Calendar
Coming up
- Nov 3, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.18) a share, on Nov 4, 2025.51
When it reported results
- Aug 6, 2026Reported quarterly or annual results39
- May 4, 2026Reported quarterly or annual results41
- Mar 3, 2026Reported quarterly or annual results42
- Nov 4, 2025Reported quarterly or annual results43
- Aug 6, 2025Reported quarterly or annual results44
- May 7, 2025Reported quarterly or annual results47
- Mar 4, 2025Reported quarterly or annual results49
- Nov 7, 2024Reported quarterly or annual results50
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
285 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 40 major events, 122 insider forms, 41 large holders, 62 other. The latest 20:
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 2026SCHEDULE 13G/A EDGAR
- Aug 11, 2026144 EDGAR
- Aug 11, 20264 OWNERSHIP DOCUMENT EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 20268-K EDGAR
- Jul 29, 2026SCHEDULE 13G/A EDGAR
- Jun 22, 202615-12G EDGAR
- Jun 22, 2026S-8 EDGAR
- Jun 12, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 11, 2026144 EDGAR
- Jun 10, 2026144 EDGAR
- Jun 9, 20268-K EDGAR
- Jun 9, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 8, 2026144 EDGAR
- Jun 8, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 8, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 8, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 8, 20264 OWNERSHIP DOCUMENT EDGAR
- Jun 3, 2026144 EDGAR
The 285 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
89 open-market trades by officers, directors and large owners since October 2021: 0 buys and 89 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 11, 2026 | SHELTON JERRELLPresident, CEO | Sale | 28,800 | $14.91 | $429.4K | Form 4 |
| Jun 11, 2026 | ZECCHINI EDWARD JChief Digital and Tech Officer | Sale | 33,600 | $14.47 | $486.2K | Form 4 |
| Jun 10, 2026 | ZECCHINI EDWARD JChief Digital and Tech Officer | Sale | 1,400 | $15.23 | $21.3K | Form 4 |
| Jun 8, 2026 | Mandalam RamkumarDirector | Sale | 23,214 | $15.44 | $358.4K | Form 4 |
| Jun 4, 2026 | STEFANOVICH ROBERTChief Financial Officer | Sale | 169,427 | $16.27 | $2.8M | Form 4 |
| Mar 23, 2026 | STEFANOVICH ROBERTChief Financial Officer | Sale | 1,094 | $8.18 | $8.9K | Form 4 |
| Mar 23, 2026 | SHELTON JERRELLPresident, CEO | Sale | 2,894 | $8.18 | $23.7K | Form 4 |
| Mar 23, 2026 | Sawicki Mark WChief Scientific Officer | Sale | 1,341 | $8.18 | $11.0K | Form 4 |
| Mar 16, 2026 | ZECCHINI EDWARD JChief Digital and Tech Officer | Sale | 2,014 | $8.00 | $16.1K | Form 4 |
| Mar 16, 2026 | SHELTON JERRELLPresident, CEO | Sale | 7,918 | $8.00 | $63.3K | Form 4 |
| Mar 16, 2026 | Sawicki Mark WChief Scientific Officer | Sale | 3,235 | $8.00 | $25.9K | Form 4 |
| Mar 16, 2026 | STEFANOVICH ROBERTChief Financial Officer | Sale | 2,743 | $8.00 | $21.9K | Form 4 |
| Mar 12, 2026 | STEFANOVICH ROBERTChief Financial Officer | Sale | 38,700 | $7.76 | $300.3K | Form 4 |
| Dec 10, 2025 | Mandalam RamkumarDirector | Sale | 11,570 | $9.99 | $115.6K | Form 4 |
| Sep 11, 2025 | Hariri Robert JDirector | Sale | 25,000 | $9.71 | $242.8K | Form 4 |
| Aug 22, 2025 | Hariri Robert JDirector | Sale | 5,000 | $8.60 | $43.0K | Form 4 |
| Aug 19, 2025 | STEFANOVICH ROBERTChief Financial Officer | Sale | 9,300 | $8.67 | $80.6K | Form 4 |
| Jul 22, 2025 | Mandalam RamkumarDirector | Sale | 40,728 | $7.24 | $294.9K | Form 4 |
| Jun 24, 2025 | SHELTON JERRELLPresident, CEO | Sale | 16,344 | $7.06 | $115.4K | Form 4 |
| Jun 24, 2025 | Mandalam RamkumarDirector | Sale | 13,321 | $7.02 | $93.5K | Form 4 |
All 89 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- CADIAN CAPITAL MANAGEMENT, LPSCHEDULE 13G/A, 4 filings Feb 14, 2024 to Aug 14, 202652
- Morgan StanleySCHEDULE 13G/A, 2 filings Feb 8, 2024 to Aug 13, 202653
- INTEGRATED CORE STRATEGIES (US) LLCSCHEDULE 13G/A, 6 filings Sep 3, 2024 to Jul 29, 202654
- VANGUARD GROUP INCSCHEDULE 13G/A, 6 filings Feb 9, 2022 to Mar 26, 202655
- BROWN CAPITAL MANAGEMENT LLCSCHEDULE 13G/A, 10 filings Mar 10, 2022 to Feb 17, 202656
- ALGER ASSOCIATES INCSCHEDULE 13G/A, 7 filings Jan 10, 2022 to Aug 14, 202557
- BlackRockSC 13G/A, 3 filings Feb 1, 2022 to Jan 26, 202458
- InvescoSC 13G/A, 2 filings Feb 9, 2022 to Feb 8, 202359
- Blackstone Holdings III L.P.SC 13D/A, 1 filing Nov 18, 202160
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Jerrell W. SheltonPresident and Chief Executive Officer | $967.8K | $2.4M61 | |
| 2025 | Robert S. StefanovichSenior Vice President and Chief Financial Officer | $597.9K | $1.1M61 | |
| 2025 | Edward ZecchiniSenior Vice President and Chief Digital and Technology Officer | $597.9K | $1.1M61 | |
| 2025 | Mark W. Sawicki, Ph.D.Chief Scientific Officer | $597.9K | $986.1K61 | |
| 2024 | Jerrell W. SheltonPresident and Chief Executive Officer | $921.2K | $1.9M61 | |
| 2024 | Edward ZecchiniSenior Vice President and Chief Digital and Technology Officer | $474.5K | $1.0M61 | |
| 2024 | Robert S. StefanovichSenior Vice President and Chief Financial Officer | $568.7K | $966.9K61 | |
| 2024 | Mark W. Sawicki, Ph.D.Chief Scientific Officer | $568.7K | $930.8K61 | |
| 2023 | Jerrell W. SheltonPresident and Chief Executive Officer | $865.6K | $2.2M61 | |
| 2023 | Mark W. Sawicki, Ph.D.Chief Scientific Officer | $534.4K | $1.0M61 | |
| 2023 | Robert S. StefanovichSenior Vice President and Chief Financial Officer | $534.4K | $1.0M61 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| BlackRock, Inc. | 4,218,434 | $66.2M | 0.0% | +237,536 |
| Cadian Capital Management, LP | 2,920,681 | $45.9M | 3.5% | −1,855,662 |
| First Eagle Investment Management, LLC | 2,542,848 | $39.9M | 0.0% | +1,797,999 |
| Assenagon Asset Management S.A. | 2,304,622 | $36.2M | 0.0% | +808,939 |
| Morgan Stanley | 2,276,741 | $35.7M | 0.0% | −2,299,989 |
| Vanguard Capital Management LLC | 2,151,943 | $33.8M | 0.0% | +33,087 |
| Millennium Management LLC | 1,724,726 | $27.1M | 0.0% | −1,245,738 |
| Fred Alger Management, LLC | 1,545,293 | $24.3M | 0.1% | −154,086 |
| Geode Capital Management, LLC | 1,312,370 | $20.6M | 0.0% | +64,235 |
| Mak Capital One LLC | 1,277,359 | $20.1M | 2.8% | −145,906 |
| State Street Corp | 1,046,875 | $16.4M | 0.0% | +62,997 |
| Dimensional Fund Advisors LP | 1,000,095 | $15.7M | 0.0% | +76,388 |
| Nuveen, LLC | 922,935 | $14.5M | 0.0% | +822,319 |
| UBS Group AG | 868,266 | $13.6M | 0.0% | −64,516 |
| Silvercrest Asset Management Group LLC | 858,684 | $13.5M | 0.1% | −42,326 |
| Meros Investment Management, LP | 743,312 | $11.7M | 3.7% | +134,239 |
| Needham Investment Management LLC | 717,000 | $11.3M | 0.3% | +357,000 |
| Brown Capital Management LLC | 670,057 | $10.5M | 2.1% | −110,507 |
| Deutsche Bank Ag\ | 654,889 | $10.3M | 0.0% | −345,787 |
| Intrinsic Edge Capital Management LLC | 630,000 | $9.9M | 1.2% | No change |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 575,364 | $9.0M | 0.0% | −202,997 |
| Vanguard Portfolio Management LLC | 562,869 | $8.8M | 0.0% | +49,235 |
| Wellington Management Group Llp | 534,930 | $8.4M | 0.0% | New |
| Mirova | 518,000 | $8.1M | 0.3% | −640,277 |
| Parkman Healthcare Partners LLC | 508,324 | $8.0M | 0.8% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Members of Congress who traded it
18 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.
| Date | Member | Trade | Amount | Vs S&P since | Filing |
|---|---|---|---|---|---|
| Sep 15, 2023 | Josh GottheimerDemocratic, House | Sale | $1,001 - $15,000 | +57.8% | Report |
| Feb 28, 2022 | Donald S. Beyer, Jr.Democratic, House | Sale | $1,001 - $15,000 | +127.7% | Report |
| Jan 31, 2022 | Donald S. Beyer, Jr.Democratic, House | Sale | $1,001 - $15,000 | +131.2% | Report |
| Jan 14, 2022 | Donald S. Beyer, Jr.Democratic, House | Sale | $1,001 - $15,000 | +129.1% | Report |
| Jan 13, 2022 | Donald S. Beyer, Jr.Democratic, House | Sale | $1,001 - $15,000 | +129.4% | Report |
| Sep 21, 2021 | Donald S. Beyer, Jr.Democratic, House | Sale | $1,001 - $15,000 | +152.6% | Report |
| Nov 24, 2020 | Gilbert Ray Cisneros, Jr.Democratic, House | Partial sale | $1,001 - $15,000 | +175.7% | Report |
| Nov 17, 2020 | Donald S. Beyer, Jr.Democratic, House | Buy | $1,001 - $15,000 | −177.7% | Report |
| Nov 13, 2020 | Josh GottheimerDemocratic, House | Partial sale | $1,001 - $15,000 | +187.0% | Report |
| Nov 2, 2020 | Donald S. Beyer, Jr.Democratic, House | Buy | $1,001 - $15,000 | −192.8% | Report |
| Jul 14, 2020 | Donald S. Beyer, Jr.Democratic, House | Sale | $1,001 - $15,000 | +191.4% | Report |
| May 7, 2020 | Donald S. Beyer, Jr.Democratic, House | Sale | $1,001 - $15,000 | +186.7% | Report |
| Feb 18, 2020 | Donald S. Beyer, Jr.Democratic, House | Buy | $1,001 - $15,000 | −135.6% | Report |
| Feb 6, 2020 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −141.6% | Report |
| Jan 17, 2020 | Gilbert Ray Cisneros, Jr.Democratic, House | Buy | $1,001 - $15,000 | −145.1% | Report |
| Jan 14, 2020 | Josh GottheimerDemocratic, House | Buy | $1,001 - $15,000 | −148.1% | Report |
| Jan 13, 2020 | Donald S. Beyer, Jr.Democratic, House | Buy | $1,001 - $15,000 | −143.4% | Report |
| Dec 23, 2019 | Donald S. Beyer, Jr.Democratic, House | Buy | $1,001 - $15,000 | −137.3% | Report |
Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).
SEC filer profile
How Cryoport, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARCryoport, Inc.1
- CIK0001124524
- Employer ID (EIN)88-03133935
- Filer statusAccelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inNevada5
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address112 Westwood Place, Suite 350, Brentwood, TN 370271
- Phone(949) 232-19001
- Shares outstanding50,649,100 as of Jul 31, 202612
- Public float$400.0M as of Jun 30, 20255
- AuditorDeloitte & Touche LLP, Nashville, Tennessee PCAOB ID 34; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceOct 20, 20051
- Filings1,070 in all: 4 (352), 8-K (203), 10-Q (55), CORRESP (46), UPLOAD (31), 144 (30), SC 13G/A (30), 3 (25)1
All 63 form types
S-1/A (25), DEF 14A (19), 10-K (18), EFFECT (18), SC 13G (17), SCHEDULE 13G/A (15), S-8 (14), D (11), 4/A (9), 424B5 (9), SC TO-I/A (9), 10QSB (8), DEFA14A (8), NT 10-Q (8), S-1 (8), 8-K/A (7), POS AM (7), 424B3 (6), PRE 14A (6), SD (6), 10SB12G/A (4), CT ORDER (4), D/A (4), REGDEX (4), S-4/A (4), 10-K/A (3), 424B1 (3), 5 (3), NT 10-K (3), S-3 (3), SC TO-I (3), 10KSB (2), 8-A12B (2), ARS (2), DEFR14A (2), PRER14A (2), S-4 (2), SB-2/A (2), SC 13D/A (2), 10-KT (1), 10-Q/A (1), 10QSB/A (1), 10SB12G (1), 15-12G (1), 25-NSE (1), 3/A (1), 8-A12G (1), CERTNAS (1), FWP (1), NT 10-Q/A (1), POSASR (1), S-3ASR (1), SB-2 (1), SC 13D (1), SCHEDULE 13G (1)
- Latest filingsAnnual report (10-K) Mar 5, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Apr 22, 2026
Latest 8-K (8-K) Aug 6, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, $0.001 par value | CYRX | NASDAQ |
From the cover page of the 10-K filed Mar 5, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks Cryoport, Inc. names in Item 1A of its 10-K filed Mar 5, 2026: 33 risks under these headings, as written.5
- Risks Related to Our Business
- As an increasingly global business, we are exposed to economic, political, and other risks in different countries which could materially reduce our sales, profitability or cash flows, or materially increase our liabilities.
- We depend on the availability of certain component products used in our solutions; delays or increased costs in the procurement of components manufactured by third parties could adversely affect our business operations, financial performance and results of operations, and we may experience customer dissatisfaction and harm to our reputation.
- Our products and services may contain errors or defects, which could result in damage to our reputation, lost revenues, diverted development resources and increased service costs, litigation and product recalls. These risks may be heightened when our products or services are used in connection with human reproductive medicine.
- Our business operations, financial performance and results of operations could be materially adversely affected by pandemics, epidemics or other public health crises, such as COVID-19.
- We will have difficulty increasing our revenues if we experience delays, difficulties or unanticipated costs in establishing the sales, marketing and distribution capabilities necessary to successfully commercialize our solutions.
- We expect to base our equipment and inventory purchasing decisions on our forecasts of customers’ demand, and if our forecasts are inaccurate, our operating results could be materially harmed.
- If we suffer a disruption or loss to our factories, facilities or distribution system due to factors outside of our control, our operations could be seriously harmed.
- Our products and services may expose us to liability in excess of our current insurance coverage.
- If we use biological and hazardous materials in a manner that causes injury, we could be liable for damages.
- We operate in a competitive industry and if we cannot compete effectively, we will lose business.
- If we successfully develop products and/or services, but those products and/or services do not achieve and maintain market acceptance, our business will not be profitable.
The other 22 risks
- The integration and operation of acquired businesses may disrupt our business and create additional expenses, and we may not achieve the anticipated benefits of the acquisitions.
- Impairment of our goodwill and other intangible assets has had, and in the future could have, a material non-cash adverse impact on our results of operations.
- Risks Related to Our Technology and Intellectual Property
- We rely upon certain critical information systems, including our Cryoportal® software platform, for the operation of our business; the failure of any critical information system could adversely impact our reputation and future revenues, and we may be required to increase our spending on data and system security.
- Cyberattacks, data incidents and breaches in the security of our information systems and networks and of the electronic and confidential information in our possession could materially adversely impact our business, financial condition and results of operations, in addition to our reputation and relationships with our employees, customers, suppliers and business partners.
- Our success depends, in part, on our ability to obtain patent protection for our solutions, preserve our trade secrets, and operate without infringing the proprietary rights of others.
- Risks Related to Regulatory and Legal Matters
- Complying with certain regulations that apply to shipments using our solutions can limit our activities and increase our cost of operations.
- Changes in trade policy, tariff and import/export regulations may have a material adverse effect on our business, financial condition and results of operations.
- We, along with our customers, are subject to various international governmental regulations. Compliance with or changes in such regulations may cause us to incur significant expenses, and if we fail to maintain satisfactory compliance with certain regulations, we may be forced to recall products and cease their manufacture and distribution, and we could be subject to civil or criminal penalties.
- We are subject to regulation by the FDA or certain similar foreign regulatory agencies, and failure to comply with such regulations could harm our reputation, business, financial condition and results of operations.
- Risks Related to Our Financial Condition
- Historically, we have incurred significant losses and we may continue to incur losses in the future.
- Our indebtedness and liabilities could limit the cash flow available for our operations and expose us to risks that could adversely affect our business, financial condition and results of operations.
- Risks Related to Our Preferred Stock
- The issuance of shares of our Series C Preferred Stock reduces the relative voting power of holders of our common stock, dilutes the ownership of such holders, and may adversely affect the market price of our common stock.
- The Series C Preferred Stockholders may exercise influence over us, including through their right to nominate for election one member to our board of directors.
- Our Series C Preferred Stock has rights, preferences, and privileges that are not held by, and are preferential to, the rights of holders of our common stock, which could adversely affect our liquidity and financial condition.
- Risks Related to Ownership of Our Common Stock
- Certain of our existing stockholders own and have the right to acquire a substantial number of shares of common stock.
- Future sales of shares of our common stock may depress the price of our shares and be dilutive to our existing stockholders.
- Our stock price has been and will likely continue to be volatile.
- We have not paid dividends on our common stock in the past and do not expect to pay dividends in the foreseeable future. Any return on investment may be limited to the value of our common stock.
- Our Articles of Incorporation allows our board of directors to issue up to 2,500,000 shares of “blank check” preferred stock.
- Provisions in our bylaws and Nevada law might discourage, delay or prevent a change of control of our Company or changes in our management and, as a result, may depress the trading price of our common stock.
- General Risk Factors
- Our ability to grow and compete in our industry will be hampered if we are unable to retain the continued service of our key professionals or to identify, hire and retain additional qualified professionals.
- If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our common stock, the price of our common stock could decline.
Legal proceedings
In the ordinary course of business, we are at times subject to various legal proceedings and disputes, including product liability claims. We currently are not aware of any such legal proceedings or claim that we believe will have, individually or in the aggregate, a material adverse effect on our business, operating results or cash flows. It is our practice to accrue for open claims based on our historical experience and available insurance coverage.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARCryoport, Inc. filings on SEC EDGAR
- 2
- 3SEC EDGARCryoport, Inc. filings on SEC EDGAR
- 4
- 5
- 6SEC EDGARCryoport, Inc. 10-K for fiscal 2025
- 7SEC EDGARCryoport, Inc. 10-K for fiscal 2019
- 8SEC EDGARCryoport, Inc. 10-K for fiscal 2020
- 9SEC EDGARCryoport, Inc. 10-K for fiscal 2021
- 10SEC EDGARCryoport, Inc. 10-K for fiscal 2022
- 11SEC EDGARCryoport, Inc. 10-Q for fiscal 2026
- 12SEC EDGARCryoport, Inc. 10-Q for fiscal 2026
- 13SEC EDGARCryoport, Inc. 10-K for fiscal 2019
- 14
- 15
- 16SEC EDGARPeter Berry, Chief executive officer
- 17SEC EDGARJerrell Shelton, President
- 18
- 19
- 20
- 21SEC EDGARJerrell Shelton, Officer
- 22
- 23
- 24
- 25SEC EDGARMichael Bartholomew, Officer
- 26SEC EDGARCarlton M. Johnson, Secretary
- 27SEC EDGARLinda Baddour, Board member
- 28SEC EDGARRam M. Jagannath, Board member
- 29SEC EDGARDaniel M. Hancock, Board member
- 30SEC EDGARRobert J. Hariri, Board member
- 31SEC EDGARRamkumar Mandalam, Board member
- 32SEC EDGARRichard G. Rathmann, Board member
- 33SEC EDGAREdward J. Zecchini, Board member
- 34SEC EDGARJerrell Shelton, Board member
- 35SEC EDGARKaren M. Muller, Board member
- 36SEC EDGARJohn H. Bonde, Board member
- 37SEC EDGARLarry G. Stambaugh, Board member
- 38SEC EDGARAdam Michelin, Board member
- 39SEC EDGARResults of operations
- 40SEC EDGARShareholder vote
- 41SEC EDGARResults of operations
- 42SEC EDGARResults of operations
- 43SEC EDGARResults of operations
- 44SEC EDGARResults of operations
- 45
- 46SEC EDGARShareholder vote
- 47SEC EDGARResults of operations
- 48
- 49SEC EDGARResults of operations
- 50SEC EDGARResults of operations
- 51NasdaqNasdaq calendar
- 52
- 53
- 54
- 55
- 56
- 57
- 58SEC EDGARBlackRock SC 13G/A on Cryoport, Inc.
- 59SEC EDGARInvesco SC 13G/A on Cryoport, Inc.
- 60
- 61